Comparative Pharmacology
Head-to-head clinical analysis: REVATIO versus STAXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVATIO versus STAXYN.
REVATIO vs STAXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVATIO (sildenafil) is a phosphodiesterase type 5 (PDE5) inhibitor. By inhibiting PDE5, it increases cyclic guanosine monophosphate (cGMP) levels in pulmonary vascular smooth muscle, leading to vasodilation and reduced pulmonary vascular resistance.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
20 mg orally three times daily, administered 4-6 hours apart.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
None Documented
None Documented
Terminal elimination half-life ~4 hours (range 3-5 hours) in steady state; similar in pulmonary arterial hypertension patients.
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Primarily hepatic metabolism (CYP3A4) to N-desmethyl sildenafil (active). Renal excretion accounts for ~80% as metabolites; ~13% fecal.
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor